Total HLA Class I Antigen Loss with the Downregulation of Antigen-Processing Machinery Components in Two Newly Established Sarcomatoid Hepatocellular Carcinoma Cell Lines

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2019 Jan 17

PMID 30648121

Citations 4

Authors

Wei-Yi Lei

Shih-Chieh Hsiung

Shao-Hsuan Wen

Chin-Hsuan Hsieh

Chien-Lin Chen

Christopher Glenn Wallace

Chien-Chung Chang

Shuen-Kuei Liao

Affiliations

Soon will be listed here.

Abstract

Limited information is currently available concerning HLA class I antigen abnormalities in sarcomatoid hepatocellular carcinoma (sHCC). Here, we have analyzed the growth characteristics and HLA class I antigen status of four sHCC cell lines (sHCC29, sHCC63, sHCC74, and SAR-HCV); the first three were newly established in this study. Among the four, sHCC29 showed the highest growth rate and tumorigenicity in NOD-SCID mice. Unlike sHCC74 and SAR-HCV, both sHCC29 and sHCC63 had no detectable surface HLA class I antigen expression, alongside undetected intracellular -microglobulin ( m) and marked HLA class I heavy chain and selective antigen-processing machinery (APM) component downregulation. The loss of m in sHCC29 and sHCC63 was caused by a >49 kb deletion across the locus, while their downregulation of APM components was transcriptional, reversible by IFN- only in several components. m was also undetected in the primary HCC lesions of the patients involved, indicating its relevance. We report for the first time HLA class I antigen loss with underlying gene deficiency and APM defects in 50% (2 of 4) of the sHCC cell lines tested. These findings may have implications for a proper design of T cell immunotherapy for the treatment of sHCC patients.

Citing Articles

IFDlong: an isoform and fusion detector for accurate annotation and quantification of long-read RNA-seq data.

Wang W, Li Y, Ko S, Feng N, Zhang M, Liu J bioRxiv. 2024; .

PMID: 38798496 PMC: 11118288. DOI: 10.1101/2024.05.11.593690.

Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response.

Sverchkova A, Burkholz S, Rubsamen R, Stratford R, Clancy T BMC Med Genomics. 2024; 17(1):37.

PMID: 38281021 PMC: 10821267. DOI: 10.1186/s12920-024-01808-8.

Impaired intratumoral dendritic cell function and potential predictive value of dendritic cell markers for metastasis in malignant salivary gland tumors.

Gama-Cuellar A, Diaz K, Calleja M, Saavedra G, Ramirez-Amador V, Corro J Med Oral Patol Oral Cir Bucal. 2023; 29(2):e273-e279.

PMID: 37992142 PMC: 10945878. DOI: 10.4317/medoral.26248.

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma.

Liu Q, Tian Y, Li Y, Zhang W, Cai W, Liu Y J Immunother Cancer. 2020; 8(2).

PMID: 33323464 PMC: 7745518. DOI: 10.1136/jitc-2020-001748.

References

Desai S, Wang X, Noronha E, Zhou Q, Rebmann V, Grosse-Wilde H . Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. J Immunol. 2000; 165(6):3275-83. DOI: 10.4049/jimmunol.165.6.3275. View

Parkin D, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2):153-6. DOI: 10.1002/ijc.1440. View

Carter P . Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2002; 1(2):118-29. DOI: 10.1038/35101072. View

Tai D, Chen C, Chang T, Chen S, Liao L, Kuo C . Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role of viral infection. J Gastroenterol Hepatol. 2002; 17(6):682-9. DOI: 10.1046/j.1440-1746.2002.02747.x. View

Huang J, Cai M, Wei D . HLA class I expression in primary hepatocellular carcinoma. World J Gastroenterol. 2002; 8(4):654-7. PMC: 4656315. DOI: 10.3748/wjg.v8.i4.654. View

Thiery J . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-54. DOI: 10.1038/nrc822. View

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Nishi H, Taguchi K, Asayama Y, Aishima S, Sugimachi K, Nawata H . Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. J Gastroenterol Hepatol. 2003; 18(4):415-23. DOI: 10.1046/j.1440-1746.2003.02888.x. View

10.

Garcia-Lora A, Algarra I, Garrido F . MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003; 195(3):346-55. DOI: 10.1002/jcp.10290. View

11.

Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F . Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol. 2003; 171(4):1918-26. DOI: 10.4049/jimmunol.171.4.1918. View

12.

Ogino T, Wang X, Ferrone S . Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods. 2003; 278(1-2):33-44. DOI: 10.1016/s0022-1759(03)00224-2. View

13.

Atkins D, Ferrone S, Schmahl G, Storkel S, Seliger B . Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J Urol. 2004; 171(2 Pt 1):885-9. DOI: 10.1097/01.ju.0000094807.95420.fe. View

14.

Chang C, Campoli M, Restifo N, Wang X, Ferrone S . Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol. 2005; 174(3):1462-71. PMC: 2245899. DOI: 10.4049/jimmunol.174.3.1462. View

15.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

16.

Wang X, Campoli M, Cho H, Ogino T, Bandoh N, Shen J . A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods. 2005; 299(1-2):139-51. DOI: 10.1016/j.jim.2005.02.006. View

17.

Bandoh N, Ogino T, Cho H, Hur S, Shen J, Wang X . Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens. 2005; 66(3):185-94. DOI: 10.1111/j.1399-0039.2005.00462.x. View

18.

Cochran A, Huang R, Lee J, Itakura E, Leong S, Essner R . Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006; 6(9):659-70. DOI: 10.1038/nri1919. View

19.

Idobe-Fujii Y, Ogi N, Hosho K, Koda M, Murawaki Y, Horie Y . Hepatocellular carcinoma with sarcomatous change arising after eradication of HCV via interferon therapy. Clin Imaging. 2006; 30(6):416-9. DOI: 10.1016/j.clinimag.2006.07.004. View

20.

Lao X, Chen D, Zhang Y, Xiang J, Guo R, Lin X . Primary carcinosarcoma of the liver: clinicopathologic features of 5 cases and a review of the literature. Am J Surg Pathol. 2007; 31(6):817-26. DOI: 10.1097/01.pas.0000213431.07116.e0. View